![a hand holding a double helix](https://phgkb.cdc.gov/GAPPKBImage/images/2016-06_gene_editing.jpg)
![](https://phgkb.cdc.gov/PHGKB/images/Whats_new.jpg)
Last Posted: Jan 31, 2020
- Prime Time for Genome Editing?
Urnov Fyodor D et al. The New England journal of medicine 2020 01 (5) 481-484 - Genome Editing for Mucopolysaccharidoses.
Poletto Edina et al. International journal of molecular sciences 2020 Jan 21(2) - Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.
Li Hongyi et al. Signal transduction and targeted therapy 2020 1 - Beyond Mendelian Genetics: Anticipatory Biomedical Ethics and Policy Implications for the Use of CRISPR Together with Gene Drive in Humans.
Nestor Michael W et al. Journal of bioethical inquiry 2020 Jan - Navigating 2020 and beyond
Nature Genetics editorial, January 7, 2020 - Quest to use CRISPR against disease gains ground
H Ledford, Nature, January 6, 2020 - Gene Therapies Make It to Clinical Trials
L Marsa, Discover, December 2020 - Gene editing prospects for treating inherited retinal diseases.
Benati Daniela et al. Journal of medical genetics 2019 Dec - Safety of Germline Genome Editing for Genetically Related "Future" Children as Perceived by Parents.
Ishii Tetsuya et al. The CRISPR journal 2019 Nov - Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
Diakatou Michalitsa et al. International journal of molecular sciences 2019 May 20(10)
No hay comentarios:
Publicar un comentario